Health News Releases

June 27, 2024 13:58

ENCell Presents the Phase 1 Clinical Trial Results of EN001 for Charcot-Marie-Tooth Disease at the PNS conference

ENCell Co., Ltd., a biotech in South Korea specializing in Cell and Gene therapy (CGT), presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell

June 27, 2024 13:20

PQE Group Launches AI and Data Analytics Division: Innovation in the Service of Life Science

PQE Group, a leading consultancy in the Life Science sector, announces the consolidation of its new Regulated Artificial Intelligence & Data Analytics division operating since the initiation of AI bas

June 26, 2024 14:45

Kenvue Releases Inaugural Healthy Lives Mission Report

Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the world’s largest pure-play consumer health company by revenue, today released its first-ever Healthy Lives Mission Report and shared how the Co

June 26, 2024 12:00

RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors

RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, F

June 25, 2024 09:43

Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unres

June 25, 2024 09:26

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54085563&newsitemid=20240624910432&lan=en-US&anchor=TSE%3A4

June 23, 2024 16:00

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri (https://www.esri.com/en-us/about/ab

June 23, 2024 13:54

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, to

June 23, 2024 12:47

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment

June 21, 2024 13:40

QPS Announces New Global Clinical Research Operations Leadership

QPS, a leading global contract research organization (CRO), is pleased to announce new clinical research operations leadership. This new clinical leadership will further align the existing global medi

June 21, 2024 11:25

C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products

C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to ac

June 20, 2024 14:15

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54067141&newsitemid=20240618911375&lan=en-US&anchor=%28TSE%3A4502%2FNY

June 19, 2024 16:55

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation

June 19, 2024 15:15

Kirin Holdings Commences Tender Offer To Make FANCL A Wholly-Owned Subsidiary

Kirin Holdings Company, Limited (Kirin Holdings) (TOKYO: 2503) has decided to acquire additional shares of common stock of FANCL Corporation (FANCL) (TOKYO: 4921) through a tender offer and share warr

June 19, 2024 10:00

Medidata Launches Clinical Data Studio, Leveraging AI to Modernize the Data Experience in Clinical Trials

Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=54053800&newsitemid=20240618137167&lan=en-US&anchor=Medidata&index=1&md5=9b4ee92db6a3a74cfb7

June 18, 2024 15:35

Carestream Secures Crucial Business Partner Agreement in Peru

Carestream Health recently secured an agreement with Distribuidora Diagnostica Medica SAC (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdmdperu.com%2F&esheet=54063578&newsitemid=2

June 18, 2024 09:05

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54062720&newsitemid=20240617592767&lan=en-US&anchor=TSE%3A4

June 16, 2024 10:00

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54061414&newsitemid=20240614852542&lan=en-US&anchor=TSE%3A4502%2FNYSE%

June 13, 2024 14:15

RegenLab France Receives Prestigious EU-EIB Innovation Champion Award

RegenLab (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftrack.regenlab.com%2Fe%2F915601%2Ffr-accueil-%2Fnh859%2F499945919%2Fh%2FMJGMMXyPSguyCEA8gEgmux2pgRtnhNF3rpVyUTCRZ9Y&esheet=5

June 12, 2024 10:25

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

AOP Orphan Pharmaceuticals GmbH (AOP Health) continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association

June 07, 2024 11:55

Erbe Elektromedizin inaugurates new competence center for medical instruments in Rangendingen, Germany, and expands its capacities for customers all over the world

Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the larges

June 05, 2024 11:20

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journ

June 04, 2024 10:05

Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors

Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54024712&newsitemid=20240602519106&lan=en-US&anchor=Masimo&index=1&md5=2fa389b04192756b6c102775397cd8f2)

June 04, 2024 09:32

Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to imp

June 04, 2024 08:57

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

Takeda (TSE: 4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54024400&newsitemid=20240531655762&lan=en-US&anchor=TSE%3A

News by Region

News by Industry